Publications

Sort by: [ Author  (Asc)] Title Type Year
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
V
Vinhas, Raquel, Alexandra Lourenço, Susana Santos, Marcos Lemos, Patrícia Ribeiro, Aida Botelho de Sousa, Pedro V. Baptista, and Alexandra R. Fernandes. A novel BCR-ABL1 mutation in a patient with Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia. OncoTargets and Therapy, 2018.
Vinhas, Raquel, Rita Mendes, Alexandra R. Fernandes, and Pedro V. Baptista. "Nanoparticles—Emerging Potential for Managing Leukemia and Lymphoma." Front. Bioeng. Biotechnol 5 (2017): 79. AbstractWebsite

Nanotechnology has become a powerful approach to improve the way we diagnose and treat cancer. In particular, nanoparticles possess unique features for enhanced sensitivity and selectivity for earlier detection of circulating cancer biomarkers. In vivo, nanoparticles enhance the therapeutic efficacy of anticancer agents when compared to conventional chemotherapy, improving vectorization and delivery, and helping to overcome drug resistance. Nanomedicine has been mostly focused on solid cancers due to take advantage from the enhanced permeability and retention (EPR) effect experienced by tissues in the close vicinity of tumors, which enhance nanomedicine’s accumulation and, consequently, improve efficacy. Nanomedicines for leukemia and lymphoma, where EPR effect is not a factor, are addressed differently from solid tumors. Nevertheless, nanoparticles have provided innovative approaches to simple and non-invasive methodologies for diagnosis and treatment in liquid tumors. In this review, we consider the state of the art on different types of nanoconstructs for the management of liquid tumors, from pre-clinical studies to clinical trials. We also discuss the advantages of nanoplatforms for theranostics and the central role played by nanoparticles in this combined strategy.

Vinhas, Raquel, Alexandra Lourenco, Susana Santos, Patricia Ribeiro, Madalena Silva, Aida Botelho de Sousa, Pedro V. Baptista, and Alexandra R. Fernandes. "A double Philadelphia chromosome-positive chronic myeloid leukemia patient, co-expressing P210(BCR-ABL1) and P195(BCR-ABL1) isoforms." Haematologica 103 (2018): E549-E552. Abstract

n/a

Vinhas, Raquel, Milton Cordeiro, Pedro Pedrosa, Alexandra R. Fernandes, and Pedro V. Baptista. "Current trends in molecular diagnostics of chronic myeloid leukemia." Leukemia & Lymphoma (2016): 1-14. AbstractWebsite

Nearly 1.5 million people worldwide suffer from chronic myeloid leukemia (CML), characterized by the genetic translocation t(9;22)(q34;q11.2), involving the fusion of the Abelson oncogene (ABL1) with the breakpoint cluster region (BCR) gene. Early onset diagnosis coupled to current therapeutics allow for a treatment success rate of 90, which has focused research on the development of novel diagnostics approaches. In this review, we present a critical perspective on current strategies for CML diagnostics, comparing to gold standard methodologies and with an eye on the future trends on nanotheranostics.

Vinhas, Raquel, Milton Cordeiro, Fábio Carlos, Soraia Mendo, Alexandra Fernandes, Sara Figueiredo, and Pedro Baptista. "Gold nanoparticle-based theranostics: disease diagnostics and treatment using a single nanomaterial." Journal of Nanobiosensors in Disease Diagnosis (2015): 11-23. AbstractWebsite

Nanotheranostics takes advantage of nanotechnology-based systems in order to diagnose and treat a specific disease. This approach is particularly relevant for personalized medicine, allowing the detection of a disease at an early stage, to direct a suitable therapy toward the target tissue based on the molecular profile of the altered phenotype, subsequently facilitating disease monitoring and following treatment. A tailored strategy also enables to reduce the off-target effects associated with universal treatments and improve the safety profile of a given treatment. The unique optical properties of gold nanoparticles, their ease of surface modification, and high surface-to-volume ratio have made them central players in this area. By combining imaging, targeting, and therapeutic agents in a single vehicle, these nanoconjugates are (ought to be) an important tool in the clinics. In this review, the multifunctionality of gold nanoparticles as theranostics agents will be highlighted, as well as the requirements before the translation of these nanoplatforms into routine clinical practice.

Vinhas, Raquel, Alexandra R. Fernandes, and Pedro V. Baptista. "Molecular Diagnostics of Chronic Myeloid Leukemia - precision medicine via gold nanoparticles." In In CDx and precision medicine for hematologic malignancies, edited by Il-Jin Kim, 205-230. PanStanford Publishing, 2018.
Vinhas, Raquel, Rita Mendes, Alexandra R. Fernandes, and Pedro V. Baptista. "Nanoparticles-Emerging Potential for Managing Leukemia and Lymphoma." Frontiers in Bioengineering and Biotechnology 5 (2017). Abstract

n/a